610 related articles for article (PubMed ID: 8636997)
1. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
Chen CR; Malik M; Snyder M; Drlica K
J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
[TBL] [Abstract][Full Text] [Related]
2. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
Heddle JG; Lu T; Zhao X; Drlica K; Maxwell A
J Mol Biol; 2001 Jun; 309(5):1219-31. PubMed ID: 11399091
[TBL] [Abstract][Full Text] [Related]
3. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
5. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
6. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals.
Sáenz Y; Zarazaga M; Briñas L; Ruiz-Larrea F; Torres C
J Antimicrob Chemother; 2003 Apr; 51(4):1001-5. PubMed ID: 12654733
[TBL] [Abstract][Full Text] [Related]
7. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones.
Malik M; Zhao X; Drlica K
Mol Microbiol; 2006 Aug; 61(3):810-25. PubMed ID: 16803589
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action of and resistance to ciprofloxacin.
Hooper DC; Wolfson JS; Ng EY; Swartz MN
Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
[TBL] [Abstract][Full Text] [Related]
9. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
Barnard FM; Maxwell A
Antimicrob Agents Chemother; 2001 Jul; 45(7):1994-2000. PubMed ID: 11408214
[TBL] [Abstract][Full Text] [Related]
10. Effect of anaerobic growth on quinolone lethality with Escherichia coli.
Malik M; Hussain S; Drlica K
Antimicrob Agents Chemother; 2007 Jan; 51(1):28-34. PubMed ID: 17043118
[TBL] [Abstract][Full Text] [Related]
11. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Shultz TR; Tapsall JW; White PA
Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998.
Su X; Lind I
Antimicrob Agents Chemother; 2001 Jan; 45(1):117-23. PubMed ID: 11120953
[TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
Gould KA; Pan XS; Kerns RJ; Fisher LM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
[TBL] [Abstract][Full Text] [Related]
14. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
15. [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].
Gushchin AE; Ladygina VG; Govorun VM
Mol Gen Mikrobiol Virusol; 1999; (4):19-24. PubMed ID: 10621934
[TBL] [Abstract][Full Text] [Related]
16. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.
Heddle JG; Blance SJ; Zamble DB; Hollfelder F; Miller DA; Wentzell LM; Walsh CT; Maxwell A
J Mol Biol; 2001 Apr; 307(5):1223-34. PubMed ID: 11292337
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
18. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes.
Casson N; Greub G
Int J Antimicrob Agents; 2006 Jun; 27(6):541-4. PubMed ID: 16697560
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the molecular mechanisms of quinolone resistance in Yersinia enterocolitica O:3 clinical isolates.
Capilla S; Ruiz J; Goñi P; Castillo J; Rubio MC; Jiménez de Anta MT; Gómez-Lus R; Vila J
J Antimicrob Chemother; 2004 Jun; 53(6):1068-71. PubMed ID: 15117921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
